RxDoctor Payments Data

Ravi Patel, MD

Internal Medicine · Addison, TXNPI 1093764169

Payments from drug & device makers

$826in general payments, 2019–2025

Across 32 payments — averaging $25.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Gilead$264
  • Johnson & Johnson Surgical Vision, Inc.$206
  • Novo Nordisk$138
  • Abiomed$80
  • Exact Sciences$49
  • Eisai Inc.$22
  • plus $66 from 4 others

What the payments were for

  • Food & beverage$826100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$826 in reported general payments places this provider in the 65th percentile of 7,675 internal medicine providers in Texas.

See all internal medicine providers in Texas

Medicare billing

Part B allowed, 2024
$233,162
Medicare patients
485
Services billed
2,515

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban27$15,682
Potassium Chloride65$2,254
Atorvastatin Calcium128$1,511
Levothyroxine Sodium85$1,167
Desmopressin Acetate11$1,152
Metoprolol Succinate77$1,039
Pantoprazole Sodium58$995
Bumetanide23$896
Fluticasone Propionate39$887
Gabapentin27$770
Metformin Hcl47$691
FenofibrateFenofibrate Nanocrystallized13$691
Montelukast Sodium25$655
Amlodipine Besylate60$646
Tamsulosin Hcl24$477

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$20$15,68227 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 7,675 internal medicine providers in Texas.

Other internal medicine in Addison

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →